ESMO Strikes Directly at the Scene After the progress of first-line treatment, the results of "re-challenge" immunotherapy were unveiled at ESMO: the first phase III study

The European Society for Internal Oncology (ESMO) Annual Meeting is the most prestigious and influential oncology conference

In the oral presentation, Professor Mustafa Ozguroglu presented the results of the EMPOWER-Lung 1 study: the results of a 3-year follow-up of 1-line cemiplimab versus chemotherapy in 50% of patients ≥ PD-L1, and the results of

1

background

method

outcome

conclusion

• Results at 3-year follow-up showed that although the crossover rate was 75%, cemiplimab improved PFS and OS compared with chemotherapy (compared with 1-year follow-up
  ).
  
  
• This study is the first Phase III study
  to challenge immunotherapy after advances in first-line PD-1 monotherapy.
  
  The study reported that patients who continued to use cemiplimab and join chemotherapy (second-line therapy) after disease progression continued to confer meaningful and lasting ORR and OS benefits
  .
  
  
• Compared with monotherapy chemotherapy (after the progression of treatment with first-line immune checkpoint inhibitors) (historical data), the combination regimen is more advantageous as a second-line treatment with better
  ORR and OS outcomes.
  
  
• The findings support cemiplimab as a first-line chemotherapy-free option for PD-L1 ≥ 50% of patients
  .